Harvoni is a combination of ledipasvir and sofosbuvir approved by the FDA in 2014. The medicine is classified as an antiviral direct-acting agent, intended for adults and children three years and older with genotypes 1, 4, 5, and 6 of hepatitis C virus infection. It is available in two forms: oral tablets and pellets, the latter of which can be mixed with soft foods for easy consumption. https://medium.com/@alexjackson121254/cost-of-harvoni-pricing-insurance-and-saving-options-ea0f8eb20ddd